Open access
Aug 2026
PARP Inhibitors plus Anlotinib as Bridging Therapy for Armored CAR‐T Cells in Ovarian Cancer Enhances Infiltration and Antitumor Efficacy
The findings support a clinically actionable bridging therapy with translational potential for potentiating CAR‐T cell therapy in ovarian cancer and highlight bridging therapy as a translational approach to improve CAR‐T cell access and efficacy in solid tumors.
Hua-Yi Li, Minghua Xiang, Qiuyang Xu et al.
· Advancement of science · 0 citations